Cogentin (Biperiden) for Seroquel-Associated Tremors
Yes, Cogentin (biperiden) can effectively treat tremors associated with Seroquel (quetiapine), as anticholinergic agents like biperiden are established treatments for antipsychotic-induced extrapyramidal symptoms including tremor. 1
Understanding the Problem
Quetiapine can cause extrapyramidal symptoms (EPS) including tremor, though it does so less frequently than typical antipsychotics. The FDA label documents that tremor occurs as an adverse reaction in clinical trials, with extrapyramidal symptoms occurring in 12.9% of adolescent patients with schizophrenia versus 5.3% on placebo 2. The label specifically lists tremor, muscle rigidity, and other parkinsonian symptoms as recognized adverse effects 2.
Treatment Approach
Biperiden is an appropriate first-line anticholinergic agent for managing quetiapine-induced tremor. Research demonstrates that biperiden at 2 mg twice daily effectively relieves neuroleptic-induced parkinsonian extrapyramidal symptoms, including tremor 1. The study showed biperiden was equally effective as amantadine and did not worsen other movement disorders 1.
Key Clinical Considerations:
- Dose: Start with biperiden 2 mg twice daily, which has proven efficacy 1
- Onset: Improvement typically occurs within 2 weeks of treatment 1
- Alternative: If biperiden is unavailable or ineffective, amantadine 100 mg twice daily provides equivalent benefit 1
Important Caveats
Before prescribing biperiden, confirm the tremor is truly drug-induced rather than an underlying condition. Drug-induced tremor from quetiapine typically:
- Appears after medication initiation or dose increase
- Resembles parkinsonian tremor (resting tremor with rigidity)
- Improves with anticholinergic treatment 3, 4
If tremor persists beyond one year despite stopping quetiapine, consider underlying Parkinson's disease rather than pure drug effect 5. A recent case report documented a patient whose tremor on quetiapine and lithium persisted after discontinuation, ultimately diagnosed with idiopathic Parkinson's disease 5.
Deprescribing Considerations
The Mayo Clinic guidelines classify quetiapine among atypical antipsychotics that should be tapered when possible in older adults due to cognitive impairment, falls risk, and FDA black box warnings for dementia-related mortality 6. If the patient is elderly or the indication for quetiapine is weak, consider tapering quetiapine rather than adding biperiden, as this reduces polypharmacy burden and anticholinergic side effects (confusion, urinary retention, constipation) 6.
Monitoring
Watch for anticholinergic side effects from biperiden including:
- Cognitive impairment and delirium (especially in older adults) 6
- Dry mouth, constipation, urinary retention
- Blurred vision
The combination of quetiapine (which has some anticholinergic properties) plus biperiden increases total anticholinergic burden, particularly problematic in elderly patients 6.